Fine Comparison of the Efficacy and Safety Between GB242 and Infliximab in Patients with Rheumatoid Arthritis: A Phase III Study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fine Comparison of the Efficacy and Safety Between GB242 and Infliximab in Patients with Rheumatoid Arthritis: A Phase III Study
Authors
Keywords
-
Journal
Rheumatology and Therapy
Volume 9, Issue 1, Pages 175-189
Publisher
Springer Science and Business Media LLC
Online
2021-11-22
DOI
10.1007/s40744-021-00396-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
- (2020) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects
- (2018) Tan Zhang et al. BIODRUGS
- Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
- (2018) Laura Chadwick et al. Current Rheumatology Reports
- The changing landscape of biosimilars in rheumatology
- (2016) Thomas Dörner et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
- (2015) Jung-Yoon Choe et al. ANNALS OF THE RHEUMATIC DISEASES
- Biosimilars for the management of rheumatoid arthritis: economic considerations
- (2015) László Gulácsi et al. Expert Review of Clinical Immunology
- Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNFαBlockers in Rheumatoid Arthritis and Spondyloarthritis Patients
- (2015) Inesa Arstikyte et al. Biomed Research International
- The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study
- (2014) Marita Cross et al. ANNALS OF THE RHEUMATIC DISEASES
- Physicochemical characterization of Remsima®
- (2014) Soon Kwan Jung et al. mAbs
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
- (2013) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
- (2013) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: An achievable target?
- (2012) Vittorio Modena et al. AUTOIMMUNITY REVIEWS
- Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice
- (2012) Jaclyn Anderson et al. ARTHRITIS CARE & RESEARCH
- American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
- (2011) D. T. Felson et al. ANNALS OF THE RHEUMATIC DISEASES
- Societal cost of rheumatoid arthritis patients in the US
- (2009) Howard Birnbaum et al. CURRENT MEDICAL RESEARCH AND OPINION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started